Free Trial

Climb Bio (CLYM) Competitors

Climb Bio logo
$1.48 0.00 (0.00%)
As of 04:00 PM Eastern

CLYM vs. GOSS, CYRX, ETON, HUMA, CMPS, ATXS, AURA, ARCT, GLUE, and RNAC

Should you be buying Climb Bio stock or one of its competitors? The main competitors of Climb Bio include Gossamer Bio (GOSS), CryoPort (CYRX), Eton Pharmaceuticals (ETON), Humacyte (HUMA), COMPASS Pathways (CMPS), Astria Therapeutics (ATXS), Aura Biosciences (AURA), Arcturus Therapeutics (ARCT), Monte Rosa Therapeutics (GLUE), and Cartesian Therapeutics (RNAC). These companies are all part of the "pharmaceutical products" industry.

Climb Bio vs. Its Competitors

Gossamer Bio (NASDAQ:GOSS) and Climb Bio (NASDAQ:CLYM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

Climb Bio has a net margin of 0.00% compared to Gossamer Bio's net margin of -41.12%. Climb Bio's return on equity of -43.95% beat Gossamer Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Gossamer Bio-41.12% -128.98% -15.52%
Climb Bio N/A -43.95%-42.94%

In the previous week, Gossamer Bio and Gossamer Bio both had 1 articles in the media. Gossamer Bio's average media sentiment score of 0.00 equaled Climb Bio'saverage media sentiment score.

Company Overall Sentiment
Gossamer Bio Neutral
Climb Bio Neutral

Gossamer Bio has a beta of 1.86, indicating that its share price is 86% more volatile than the S&P 500. Comparatively, Climb Bio has a beta of -0.13, indicating that its share price is 113% less volatile than the S&P 500.

Gossamer Bio currently has a consensus price target of $8.25, suggesting a potential upside of 363.48%. Climb Bio has a consensus price target of $9.00, suggesting a potential upside of 508.11%. Given Climb Bio's stronger consensus rating and higher probable upside, analysts plainly believe Climb Bio is more favorable than Gossamer Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gossamer Bio
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
Climb Bio
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.25

81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 69.8% of Climb Bio shares are held by institutional investors. 6.7% of Gossamer Bio shares are held by insiders. Comparatively, 0.8% of Climb Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Gossamer Bio has higher revenue and earnings than Climb Bio. Gossamer Bio is trading at a lower price-to-earnings ratio than Climb Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gossamer Bio$114.70M3.53-$56.53M-$0.23-7.74
Climb BioN/AN/A-$73.90M-$2.38-0.62

Summary

Gossamer Bio beats Climb Bio on 8 of the 14 factors compared between the two stocks.

Get Climb Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for CLYM and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CLYM vs. The Competition

MetricClimb BioMED IndustryMedical SectorNASDAQ Exchange
Market Cap$100.01M$3.06B$5.70B$9.48B
Dividend YieldN/A2.37%4.59%3.99%
P/E Ratio-0.6220.7327.9019.95
Price / SalesN/A321.12442.19102.72
Price / CashN/A43.2336.5558.97
Price / Book0.478.308.635.90
Net Income-$73.90M-$55.19M$3.24B$258.42M
7 Day Performance1.37%5.07%3.22%1.94%
1 Month Performance14.73%17.61%10.72%12.02%
1 Year PerformanceN/A7.03%34.94%20.81%

Climb Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CLYM
Climb Bio
2.614 of 5 stars
$1.48
flat
$9.00
+508.1%
N/A$100.01MN/A-0.629
GOSS
Gossamer Bio
3.5284 of 5 stars
$1.71
+3.0%
$8.25
+382.5%
+74.8%$377.32M$114.70M-7.43180Gap Up
High Trading Volume
CYRX
CryoPort
2.0844 of 5 stars
$7.43
-0.3%
$10.88
+46.4%
-13.5%$373.52M$228.38M-3.181,186Positive News
Analyst Upgrade
Insider Trade
Analyst Revision
ETON
Eton Pharmaceuticals
2.4704 of 5 stars
$13.95
+0.4%
$29.67
+112.7%
+330.7%$372.50M$39.01M-77.5020Analyst Revision
HUMA
Humacyte
1.7259 of 5 stars
$2.42
+1.3%
$11.71
+384.1%
-67.1%$370.73M$1.57M-3.51150News Coverage
Analyst Forecast
CMPS
COMPASS Pathways
2.0146 of 5 stars
$3.88
-1.3%
$17.00
+338.1%
-36.5%$367.70MN/A-1.95120Upcoming Earnings
ATXS
Astria Therapeutics
1.3171 of 5 stars
$6.24
-1.4%
$30.00
+380.8%
-42.7%$357.23MN/A-3.3430
AURA
Aura Biosciences
2.7194 of 5 stars
$7.12
+2.4%
$22.00
+209.0%
-25.8%$349.37MN/A-3.7550Positive News
ARCT
Arcturus Therapeutics
1.7881 of 5 stars
$13.54
+5.4%
$54.00
+298.8%
-34.6%$348.50M$152.31M-5.35180
GLUE
Monte Rosa Therapeutics
2.1094 of 5 stars
$5.90
+5.2%
$15.33
+159.9%
+30.7%$345.07M$75.62M73.7690News Coverage
RNAC
Cartesian Therapeutics
1.6943 of 5 stars
$12.53
-5.6%
$40.00
+219.2%
-21.3%$344.41M$38.91M-0.2464News Coverage

Related Companies and Tools


This page (NASDAQ:CLYM) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners